Maxim Group raised its price target for Viking Therapeutics (NASDAQ:VKTX) to $8 from $5 after the company announced results of a Phase 2 hip fracture study of its VK5211 compound. The stock was changing hands at $3.07 in mid-morning trading on Nov. 28.Read More
Viking Therapeutics (NASDAQ:VKTX) announced positive top-line results from a proof-of-concept study of VK0214 in a mouse model of X-linked adrenoleukodystrophy (X-ALD).
The results showed that VK0214 rapidly reduced very long chain fatty acid (VLCFA) levels in plasma by more than 25% in treated animals, compared with vehicle controls. The study successfully achieved its primary objective, which was to demonstrate the ability of VK0214 to lower plasma VLCFA levels after six weeks of treatment.Read More